The accumulation of tau protein aggregates is a pathological hallmark in Alzheimer’s disease (AD) and other neurodegenerative diseases. However, the identity of the toxic tau conformation that propagates and induces neurodegeneration is still unknown. Anti-tau antibodies are a common tool used to differentiate between normal and pathological-associated tau forms or as passive immunotherapy in the quest to interfere with tau-mediated neurodegeneration. Here, we show that Tau13, a tau N-terminal antibody, preferentially enriches high molecular weight tau species produced in a tauopathy mouse model and AD. The data suggest that Tau13 has higher affinity to specific tau conformation presence in higher molecular weight tau species.
LeeVMY, GoedertM, TrojanowskiJQ (2001) Neurodegenerative tauopathies. Annu Rev Neurosci24, 1121–1159.
2.
IqbalK, Alonso AdelC, ChenS, ChohanMO, El-AkkadE, GongCX, KhatoonS, LiB, LiuF, RahmanA, TanimukaiH, Grundke-IqbalI (2005) Tau pathology in Alzheimer disease and other tauopathies. Biochim Biophys Acta1739, 198–210.
3.
ChongFP, NgKY, KohRY, ChyeSM (2018) Tau proteins and tauopathies in Alzheimer’s disease. Cell Mol Neurobiol38, 965–980.
4.
de CalignonA, PolydoroM, Suárez-CalvetM, WilliamC, AdamowiczDH, KopeikinaKJ, PitstickR, SaharaN, AsheKH, CarlsonGA, Spires-JonesTL, HymanBT (2012) Propagation of tau pathology in a model of early Alzheimer’s disease. Neuron73, 685–697.
5.
IbaM, GuoJL, McBrideJD, ZhangB, TrojanowskiJQ, LeeVM (2013) Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer’s-like tauopathy. J Neurosci33, 1024–1037.
6.
DujardinS, LécolleK, CaillierezR, BégardS, ZommerN, LachaudC, CarrierS, DufourN, AuréganG, WinderickxJ, HantrayeP, DéglonN, ColinM, BuéeL (2014) Neuron-to-neuron wild-type tau protein transfer through a trans-synaptic mechanism: Relevance to sporadic tauopathies. Acta Neuropathol Commun2, 14.
7.
de CalignonA, Spires-JonesTL, PitstickR, CarlsonGA, HymanBT (2009) Tangle-bearing neurons survive despite disruption of membrane integrity in a mouse model of tauopathy. J Neuropathol Exp Neurol68, 757–761.
8.
KuchibhotlaKV, WegmannS, KopeikinaKJ, HawkesJ, RudinskiyN, AndermannML, Spires-JonesTL, BacskaiBJ, HymanBT (2014) Neurofibrillary tangle-bearing neurons are functionally integrated in cortical circuits in vivo. Proc Natl Acad Sci U S A111, 510–514.
ApiccoDJ, AshPEA, MaziukB, LeBlangC, MedallaM, Al AbdullatifA, FerragudA, BotelhoE, BallanceHI, DhawanU, BoudeauS, CruzAL, KashyD, WongA, GoldbergLR, YazdaniN, ZhangC, UngCY, TripodisY, KanaanNM, IkezuT, CottoneP, LeszykJ, LiH, LuebkeJ, BryantCD, WolozinB (2018) Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo. Nat Neurosci21, 72–80.
11.
VanderweydeT, ApiccoDJ, Youmans-KidderK, AshPEA, CookC, Lummertz da RochaE, Jansen-WestK, FrameAA, CitroA, LeszykJD, IvanovP, AbisambraJF, SteffenM, LiH, PetrucelliL, WolozinB (2016) Interaction of tau with the RNA-binding protein TIA1 regulates tau pathophysiology and toxicity. Cell Rep15, 1455–1466.
12.
EhrenbergAJ, SuemotoCK, de Paula França ResendeE, PetersenC, LeiteREP, RodriguezRD, Ferretti-RebustiniREL, YouM, OhJ, NitriniR, PasqualucciCA, Jacob-FilhoW, KramerJH, GatchelJR, GrinbergLT (2018) Neuropathologic correlates of psychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis66, 115–126.
13.
JichaGA, BowserR, KazamIG, DaviesP (1997) Alz-50 and MC-1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. J Neurosci Res48, 128–32.
14.
KanaanNM, MorfiniGA, LaPointeNE, PiginoGF, PattersonKR, SongY, AndreadisA, FuY, BradyST, BinderLI (2011) Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of al phosphotransferases. J Neurosci31, 9858e9868.
15.
CombsB, HamelC, KanaanNM (2016) Pathological conformations involving the amino terminus of tau occur early in Alzheimer’s disease and are differentially detected by monoclonal antibodies. Neurobiol Dis94, 18e31.
16.
CombsB, KanaanNM (2017) Exposure of the amino terminus of tau is a pathological event in multiple tauopathies. Am J Pathol187, 1222–1229.
17.
LewisJ, McGowanE, RockwoodJ, MelroseH, NacharajuP, Van SlegtenhorstM, Gwinn-HardyK, Paul MurphyM, BakerM, YuX, DuffK, HardyJ, CorralA, LinWL, YenSH, DicksonDW, DaviesP, HuttonM (2000) Neurofibrillary tangles, amyothrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat Genet25, 402–405.
18.
LewisJ, McGowanE (2005) Rodent models of tauopathies. In Animal Models of Movement Disorders,
LeDouxM, ed. Academic Press, Burlington, pp. 529–539.
19.
SaharaN, LewisJ, DeTureM, McGowanE, DicksonDW, HuttonM, YenSH (2002) Assembly of tau in transgenic animals expressing P301L tau: Alteration of phosphorylation and solubility. J Neurochem83, 1498–1508.
20.
NobuharaCK, DeVosSL, ComminsC, WegmannS, MooreBD, RoeAD, CostantinoI, FroschMP, PitstickR, CarlsonGA, HockC, NitschRM, MontrasioF, GrimmJ, CheungAE, DunahAW, WittmannM, BussiereT, WeinrebPH, HymanBT, TakedaS (2017) Tau antibody targeting pathological species blocks neuronal uptake and interneuron propagation of tau in vitro. Am J Pathol187, 1399–1412.
